MTCR Metacrine

Metacrine to Present at SVB Leerink 10th Annual Global Healthcare Conference

Metacrine to Present at SVB Leerink 10th Annual Global Healthcare Conference

SAN DIEGO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine, will present at the SVB Leerink 10th Annual Global Healthcare Conference on Friday, February 26, 2021 at 4:20 p.m. ET.

The live webcast will be available in the investor section of the company's website at The webcast will be archived for 60 days following the presentation.

About Metacrine

Metacrine, Inc. (Nasdaq: MTCR) is a clinical-stage biopharmaceutical company building a differentiated pipeline of therapies to treat liver and gastrointestinal (GI) diseases. Metacrine has developed a proprietary farnesoid X receptor (FXR) platform utilizing a unique chemical scaffold, which has demonstrated a differentiated and improved therapeutic profile in clinical trials. The company’s two product candidates, MET409 and MET642, are currently being investigated in clinical trials as potential new treatments for non-alcoholic steatohepatitis (NASH). MET409 has completed a 12-week monotherapy trial in patients with NASH and is being evaluated in a 12-week combination trial with empagliflozin in patients with both NASH and type 2 diabetes. MET642 has completed a 14-day Phase 1 trial in healthy volunteers and is being advanced into a 16-week monotherapy trial in patients with NASH.

Contact:

Chelcie Lister

THRUST Strategic Communications

910.777.3049



EN
19/02/2021

Underlying

MTCRMetacrine

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Metacrine

 PRESS RELEASE
Free
MTCR METACRINE

Metacrine and Equillium Mutually Agree to Terminate Definitive Merger ...

Metacrine and Equillium Mutually Agree to Terminate Definitive Merger Agreement LA JOLLA, Calif., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR) and Equillium, Inc. today announced the mutual termination of their previously announced definitive merger agreement. Metacrine is continuing to evaluate all strategic opportunities. Additional information regarding the termination of the definitive merger agreement is provided set forth in a Current Report on Form 8-K filed by Metacrine with the U.S. Securities and Exchange Commission today and is available at and on Metacrine...

December 23, 2022 1 EN
 PRESS RELEASE
Free
MTCR METACRINE

Metacrine Reports Third-Quarter 2022 Results

Metacrine Reports Third-Quarter 2022 Results SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company developing differentiated therapies for patients with gastrointestinal diseases, today reported its third-quarter 2022 financial results. “We made great progress during the quarter in advancing our proposed merger with Equillium,” said Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine. “We believe that Equillium has demonstrated compelling clinical data in Lupus Nephritis and has an exciting pipeli...

November 14, 2022 1 EN
 PRESS RELEASE
Free
MTCR METACRINE

Metacrine Reports Second-Quarter 2022 Results

Metacrine Reports Second-Quarter 2022 Results SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, today reported its second-quarter 2022 financial results. “We have made meaningful progress during the quarter in evaluating strategic alternatives designed to maximize stockholder value,” said Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine. Potential strategic alternatives to be explored and evaluated may includ...

August 9, 2022 1 EN
 PRESS RELEASE
Free
MTCR METACRINE

Metacrine Reports First-Quarter 2022 Results

Metacrine Reports First-Quarter 2022 Results SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, today reported its first-quarter 2022 financial results and provided a business update. Metacrine announced today that it has engaged a strategic financial advisor and initiated a review of strategic alternatives with the goal of maximizing shareholder value. Potential strategic alternatives to be explored and evaluated may include a merger, sale, ...

May 12, 2022 1 EN
 PRESS RELEASE
Free
MTCR METACRINE

Metacrine Reports Fourth-Quarter 2021 Results

Metacrine Reports Fourth-Quarter 2021 Results SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, today reported its fourth-quarter 2021 financial results. “We continue to devote all of our development effort to bringing expanded therapeutic options to people living with ulcerative colitis (UC),” said Preston Klassen, M.D., MHS, CEO, Metacrine. “We have generated preclinical data that supports moving our MET642 program into clinical testing ...

March 30, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch